Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone

Journal of Clinical Oncology

Volumn 28, Issue 34, 2010, Pages

  Bibas, Michele ^a   Grisetti, Susanna ^a   Alba, Lucia ^a   Picchi, Giovanna ^a   Del Nonno, Franca ^a   Antinori, Andrea ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BORTEZOMIB; CYTARABINE; DEXAMETHASONE; EMTRICITABINE; GEMCITABINE; LENALIDOMIDE; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TENOFOVIR;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; MALE; MONOTHERAPY; PLASMABLASTIC LYMPHOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BORONIC ACIDS; CYTARABINE; DEOXYCYTIDINE; DEXAMETHASONE; FILGRASTIM; HIV INFECTIONS; HUMANS; LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC; MALE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PYRAZINES; THALIDOMIDE; YOUNG ADULT;

EID: 79951924653     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.0038     Document Type: Article

References (15)

1. Jaffe ES, Harris NL, Stein H, et al (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
2. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al: Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection. Blood 89:1413-1420, 1997 (Pubitemid 27080006)
3. Re A, Michieli M, Casari S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: Long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 114:1306-1313, 2009
4. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005 (Pubitemid 41007864)
5. Castillo JJ, Winer ES, Stachurski D, et al: Prognostic factors in chemotherapy- treated patients with HIV-associated plasmablastic lymphoma. Oncologist 15:293-299, 2010
6. Lacasce A, Howard O, Lib S, et al: Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: Preserved efficacy with decreased toxicity. Leuk Lymphoma 45:761-767, 2004 (Pubitemid 38256039)
7. Wiernik PH, Lossos IS, Tuscano JM, et al: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 26:4952-4957, 2008
8. Carbone A, Gloghini A: Plasmablastic lymphoma: One or more entities? Am J Hematol 83:763-764, 2008
9. Vega F, Chang CC, Medeiros LJ, et al: Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18:806-815, 2005 (Pubitemid 40780514)
10. Guan B, Zhang X, Ma H, et al: A meta-analysis of highly active anti-retroviral 12 therapy for treatment of plasmablastic lymphoma. Hematol Oncol Stem Cell Ther 3:7-12, 2010
11. Tay K, Dunleavy K, Wilson WH: Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise. Blood Rev 24:69-82, 2010
12. Reddy N, Czuczman MS: Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: Preclinical mechanistic studies. Ann Oncol [epub ahead of print on February 4, 2010]
13. Chim CS, Hwang YY, Pang C, et al: Restoration of chemosensitivity by bortezomib: Implications for refractory myeloma. Nat Rev Clin Oncol 6:237-240, 2009
14. Bortezomib, ifosfamide, carboplatin, and etoposide, with or without rituximab, in treating patients with relapsed or refractory AIDS-related non-Hodgkin lymphoma. http://www.clinicaltrials.gov
15. Laubach JP, Mahindra A, Mitsiades CS, et al: The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 23:2222-2232, 2009